liraglutide to semaglutide conversion Dose-equivalence reference based on pivotal GLP-1/dual-agonist trials: SURMOUNT-1 (tirzepatide/Zepbound, 72 weeks) STEP-1 (subcutaneous semaglutide/Wegovy, 68 weeks) OASIS-4 (oral semaglutide/Wegovy, 64 weeks). For educational comparison only—these are 2.5 mg to ml semaglutide

Mild digestive changes are common with both surgery and GLP-1 therapy

Blood level testing for bupropion is available but rarely needed

The tool also tracks total doses administered, average intervals, and adherence metrics

All faced ongoing pain under strain and were unable to fully return to their sports

Patients in the United States are filing lawsuits to hold Novo Nordisk accountable for not telling them about the full range of risks of Ozempic

Clinical trials have shown that patients can achieve substantial weight loss, often in the range of 10-15% of their body weight over 68 weeks, which is significant compared to other options available